Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
This study evaluates the effectiveness of Lu AF35700 for people with schizophrenia.
Understand this study
What is this study about?
This study evaluates the effectiveness of Lu AF35700 for people with schizophrenia.
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- San Diego and 40 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 119
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, United Kingdom, Bulgaria, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT03230864
- Official title
Show the full official title
Interventional, Randomized, Double-blind, Active-controlled Study of the Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
Recruitment & locations
San Diego, United States · Atlanta, United States · Chicago, United States
33 more locations
- Fall River, United States
- Worcester, United States
- Ann Arbor, United States
- Kalamazoo, United States
- St Louis, United States
- Omaha, United States
- Salt Lake City, United States
- Kardzhali, Bulgaria
- Novi Iskar, Bulgaria
- Pleven, Bulgaria
- Radnevo, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Aizu-Wakamatsu, Japan
- Fukushima, Japan
- Ichikawa, Japan
- Kashihara, Japan
- Kita-ku, Japan
- Kitakyushu, Japan
- Kodaira, Japan
- Kumamoto, Japan
- Kunigami, Japan
- Toyoake, Japan
- Lipetsk, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Tomsk, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Edinburgh, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Russia
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the effectiveness of Lu AF35700 for people with schizophrenia.
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Does this study involve medication?
Yes. The study involves medication, including Lu AF35700, Risperidone and Olanzapine.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
